PCSA · XBRL financial data

Processa Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PCSA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 31, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0*	—	—	—	—	—	—	—	—	—	—	—
Research and development	—	year only	—	—	—	—	—	—	—	—	—	—
General and administrative	1,016	1,149*	1,271	1,352	1,137	1,022*	1,258	—	1,827	1,588*	1,522	1,686
Operating income (loss)	(2,168)	(2,469)*	(2,810)	(3,082)	(3,425)	(2,735)*	(2,847)	—	(3,489)	(3,702)*	(3,331)	(2,336)
Interest income	86	65*	—	—	40	6*	13	—	—	year only	14	—
Other income (expense)	—	—	83	72	—	—	—	—	—	—	—	—
Net income (loss)	(2,082)	(2,405)*	(2,726)	(3,010)	(3,385)	(2,729)*	(2,834)	—	(3,437)	(3,359)*	(3,377)	(3,265)
Earnings per share, basic USD per share	(0.08)	—	(1.11)	(1.01)	(1.03)	(0.78)*	(0.30)	—	(0.07)	—	(1.29)	(1.19)
Earnings per share, diluted USD per share	(0.08)	—	(1.11)	(1.01)	(1.03)	(0.78)*	(0.30)	—	(0.07)	—	(1.29)	(1.19)
Weighted average shares, basic thousands of shares	27,003	—	2,467	2,983	3,276	3,507*	9,527	—	47,526	—	2,623	2,751
Weighted average shares, diluted thousands of shares	27,003	—	2,467	2,983	3,276	3,507*	9,527	—	47,526	—	2,623	2,751

† Share count changed about 1/21 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PCSA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 31, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	6,861	4,706	8,920	5,571	2,891	1,191	2,897	—	6,308	5,537	1,691	196
Prepaid and other current assets	1,047	926	858	1,907	1,947	682	861	—	278	134	247	1,398
Total current assets	7,907	5,632	9,800	7,478	4,838	1,874	3,758	—	6,587	5,671	1,938	2,066
Property and equipment, net	3	3	2	2	5	5	—	—	4	4	4	3
Right-of-use asset	167	146	—	—	—	71	48	—	—	—	—	—
Total assets	8,083	5,787	9,945	7,601	4,942	3,229	4,810	—	7,585	7,814	4,521	2,070
Accounts payable	346	312	455	953	712	881	553	—	727	1,057	840	1,659
Accrued liabilities	202	146	466	505	413	579	681	—	1,024	1,179	1,140	727
Total current liabilities	826	731	1,011	1,552	1,219	1,533	1,283	—	1,751	2,236	1,980	2,387
Lease liability, non-current	89	67	45	22	—	—	—	—	—	—	—	—
Total liabilities	915	797	1,061	1,577	1,221	1,533	1,283	—	1,751	2,236	1,980	2,387
Accumulated deficit	(72,964)	(75,369)	(78,095)	(81,106)	(84,490)	(87,219)	(90,054)	—	(97,424)	(100,783)	(104,160)	(107,426)
Total stockholders' equity	7,168	4,989	8,883	6,024	3,721	1,696	3,527	—	5,834	5,577	2,541	(317)
Total liabilities and equity	8,083	5,787	9,945	7,601	4,942	3,229	4,810	—	7,585	7,814	4,521	2,070
Common shares outstanding (cover page) thousands of shares	24,631	2,856	2,858	3,257	3,267	5,269	11,884	50,349	56,644	2,660	2,750	2,793

† Share count changed about 1/21 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PCSA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 31, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,082)	(2,405)*	(2,726)	(3,010)	(3,385)	(2,729)*	(2,834)	—	(3,437)	(3,359)*	(3,377)	(3,265)
Stock-based compensation	143	257*	168	153	154	155*	228	—	303*	124*	96	92*
Net cash from operating activities	(1,761)*	(2,124)*	(2,049)	(3,346)*	(3,603)*	(2,248)*	(2,730)	—	(3,484)*	(2,901)*	(3,591)	(1,996)*
Purchases of property and equipment	—	0*	—	—	—	0*	—	—	—	—	—	—
Net cash from investing activities	—	0*	—	—	—	0*	—	—	—	year only	(500)	186*
Proceeds from issuing common stock	0*	(31)*	6,282	0*	931*	549*	4,439	—	—	year only	245	315*
Proceeds from issuing equity	—	—	—	—	931*	—	—	—	2,860*	—	—	—
Net cash from financing activities	(53)*	(31)*	6,263	(3)*	926*	548*	4,436	—	2,856*	2,979*	245	315*
Net change in cash	(1,816)*	(2,154)*	4,214	(3,349)*	(2,680)*	(1,700)*	1,706	—	(628)*	(771)*	(3,846)	(1,495)*

† Share count changed about 1/21 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Processa Pharmaceuticals	196	not reported	(1,996)*	2.8M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Talphera	742	not reported	(3,924)*	51.9M	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Biovie	8,977	not reported	(4,122)*	7.5M	2.2 quarters	Q4 FY26 10-KJun 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
GT Biopharma	4,960	not reported	(4,260)*	45.1M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.